首页> 外文OA文献 >Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status

【2h】

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status

机译：评估重试IHC0，IHC1 +或鱼类阴性早期乳腺癌患者为HER2地位的潜在成本效益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Louis P. Garrison; Deepa Lalla; Melissa Brammer; Joseph B. Babigumira; Bruce Wang; Edith A. Perez;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status [J] . GarrisonJr.L.P., LallaD., BrammerM., Cancer: A Journal of the American Cancer Society . 2013,第17期

机译：评估重新测试IHC0，IHC1 +或FISH阴性的早期乳腺癌患者的HER2状态的潜在成本效益
2. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status [J] . GarrisonJr.L.P., LallaD., BrammerM., Cancer: A Journal of the American Cancer Society . 2013,第17期

机译：评估重试IHC0，IHC1 +或鱼类阴性早期乳腺癌患者的潜在成本效益为HER2状态
3. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. [J] . Im SA, Kim JW, Kim JS, Diagnostic molecular pathology : . 2011,第2期

机译：根据通过免疫组织化学和荧光原位杂交评估的HER2状态，III / IV期（M（0））晚期胃癌患者的临床病理特征。
4. Automatically diagnosing HER2 amplification status for breast cancer patients using large FISH images [C] . Salar Razavi, Gökhan Hatipoğlu, Hülya Yalçın Signal Processing and Communications Applications Conference . 2017

机译：使用大FISH图像自动诊断乳腺癌患者的HER2扩增状态
5. Boron Neutron Capture Therapy for HER2+ breast cancers: A feasibility study evaluating BNCT for potential role in breast conservation therapies. [D] . Jenkins, Peter Anthony. 2012

机译：HER2 +乳腺癌的硼中子捕获疗法：评估BNCT在乳腺癌保护疗法中潜在作用的可行性研究。
6. Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients [O] . Francesca Ligorio, Luca Zambelli, Achille Bottiglieri, 2021

机译：激素受体状态影响体重指数和高血糖对早期HER2阳性乳腺癌患者肿瘤复发风险的影响
7. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status [O] . John Souglakos, Lambros Vamvakas, Stella Apostolaki, 2006

机译：乳腺癌患者的中枢神经系统复发与晚期，循环性隐匿性肿瘤细胞的存在以及HER2 / neu状态有关
8. Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide- Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy; Annual rept. 27 Apr 2007-26 Apr 2008 [R] . Disis, M. L. 2008

机译：对接受曲妥珠单抗单一疗法的IIIB和IV期HER2阳性乳腺癌患者施用HER-2 / neu（HER2）细胞内结构域（ICD）基于肽的疫苗的II期研究;年度报告。 2007年4月27日至2008年4月26日

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status

著录项

引文网络

相似文献

相关主题

期刊订阅